Both treatment options are effective, but metabolic and bariatric surgery was linked to more significant cardiovascular risk reductions than GLP-1 medications.

When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival. 

About 38% of rads surveyed said they had defended against at least one lawsuit, with such specialists at a higher risk than others in internal medicine. 

The publicly traded imaging center operator is teaming with Saint Alphonsus Health System to jointly run five facilities in Idaho. 

Legal and compliance teams have to serve as sentinels sizing up potential legal exposure points without turning into needlers who only slow down clinical innovation.

In some cases, patients in isolated areas must travel up to 130 miles to gain access to the latest class of NETs, new data suggest.

The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal. 

New findings suggest that 99mTc-maraciclatide can help physicians more accurately identify endometriosis on imaging.

Some Omnipod 5 devices, manufactured by Insulet, are subject to the Class I recall. The products with the defect must be removed from where they are used or sold to ensure safety, as lower-than-expected insulin doses could have potentially lethal repercussions.

U.S. healthcare is in the throes of an affordability crisis. The good news is that healthcare leaders have all the evidence, tools and expertise needed to keep the predicament from becoming a plight. Can they marshal the will to wield those weapons toward that end?